Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | FPR3 | P25089 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28997883 | 0.92 | TDP1 (0.44) | CA14PAOXTDP1CTSKMAOA | |
| SCHEMBL26012286 | 0.91 | CA14 (0.42) | CA14PAOXTDP1CTSKMAOA | |
| SCHEMBL15284921 | 0.91 | CA14 (0.40) | CA14PAOXTDP1CTSKMAOA | |
| SCHEMBL22771101 | 0.90 | CA14 (0.42) | CA14PAOXTDP1CTSKMAOA | |
| SCHEMBL26012279 | 0.89 | CA14 (0.40) | CA14PAOXTDP1CTSKMAOA | |
| SCHEMBL26000280 | 0.88 | MAOA (0.54) | CA14TDP1CTSKMAOAMAOB | |
| SCHEMBL15223854 | 0.87 | PAOX (0.46) | CA14PAOXTDP1CTSKMAOA | |
| SCHEMBL3034221 | 0.87 | CA14 (0.42) | CA14PAOXTDP1CTSKMAOA | |
| SCHEMBL30999444 | 0.87 | TDP1 (0.42) | CA14PAOXTDP1CTSKMAOA | |
| SCHEMBL9354393 | 0.86 | CA14 (0.44) | CA14TDP1CTSKMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109732-A1 | LIPID AMINES | MODERNATX INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250235531-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MODERNATX, INC. (US) | 2025-07-24 | — | — | US | disclosed |
| EP-4475882-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | ModernaTX, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| EP-4423107-A1 | LIPID AMINES | ModernaTX, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118510788-A | Liposoamines | 摩登纳特斯有限公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2023154818-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MODERNATX, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023076598-A1 | LIPID AMINES | MODERNATX, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076598-A1 | LIPID AMINES | MODERNATX, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250235531-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MUC1, RNMT, FABP2 | CA14 2168/4885PAOX 4511/4885TDP1 3192/4885 |
| US-20260109732-A1 | LIPID AMINES | LDLR, NPC1, PHOSPHO1 | CA14 1404/4885PAOX 1476/4885TDP1 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.